Total Payments
$15,165
2024 Payments
$1,819
Companies
38
Transactions
582
Medicare Patients
8,289
Medicare Billing
$1.7M
Payment Breakdown by Category
Food & Beverage$12,898 (85.1%)
Travel$2,088 (13.8%)
Education$179.10 (1.2%)
Other$0.00 (0.0%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Food and Beverage | $12,898 | 555 | 85.1% |
| Travel and Lodging | $2,088 | 7 | 13.8% |
| Education | $179.10 | 20 | 1.2% |
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Boston Scientific Corporation | $1,968 | 21 | $0 (2024) |
| Novartis Pharmaceuticals Corporation | $1,375 | 83 | $0 (2024) |
| Janssen Pharmaceuticals, Inc | $1,375 | 64 | $0 (2024) |
| Medtronic Vascular, Inc. | $1,145 | 13 | $0 (2020) |
| Abbott Laboratories | $1,063 | 32 | $0 (2024) |
| Boehringer Ingelheim Pharmaceuticals, Inc. | $972.36 | 55 | $0 (2023) |
| Amgen Inc. | $904.81 | 41 | $0 (2023) |
| Lilly USA, LLC | $824.30 | 38 | $0 (2024) |
| Merck Sharp & Dohme LLC | $713.66 | 34 | $0 (2024) |
| ZOLL Services LLC (A/K/A ZOLL LifeCor Corp) | $672.64 | 26 | $0 (2024) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $1,819 | 75 | Merck Sharp & Dohme LLC ($276.33) |
| 2023 | $1,667 | 72 | Lilly USA, LLC ($292.80) |
| 2022 | $1,435 | 54 | Medtronic, Inc. ($253.66) |
| 2021 | $1,215 | 58 | Novartis Pharmaceuticals Corporation ($167.59) |
| 2020 | $1,048 | 49 | Amgen Inc. ($130.37) |
| 2019 | $4,987 | 122 | Boston Scientific Corporation ($1,655) |
| 2018 | $1,730 | 90 | Boehringer Ingelheim Pharmaceuticals, Inc. ($290.52) |
| 2017 | $1,264 | 62 | Janssen Pharmaceuticals, Inc ($385.96) |
All Payment Transactions
582 individual payment records from CMS Open Payments — Page 1 of 24
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/19/2024 | Lilly USA, LLC | MOUNJARO (Drug), ZEPBOUND | Food and Beverage | In-kind items and services | $28.31 | General |
| Category: Diabetes | ||||||
| 12/18/2024 | Novo Nordisk Inc | Ozempic (Drug), Rybelsus | Food and Beverage | In-kind items and services | $25.03 | General |
| Category: Diabetes | ||||||
| 12/10/2024 | Abbott Laboratories | TENDRIL (Device) | Food and Beverage | In-kind items and services | $47.37 | General |
| Category: Cardiac Rhythm Management | ||||||
| 12/09/2024 | Merck Sharp & Dohme LLC | VERQUVO (Drug), VERQUVO | Food and Beverage | In-kind items and services | $24.45 | General |
| Category: CARDIOVASCULAR | ||||||
| 12/08/2024 | Novo Nordisk Inc | Ozempic (Drug), Rybelsus | Food and Beverage | In-kind items and services | $17.54 | General |
| Category: Diabetes | ||||||
| 11/22/2024 | Novo Nordisk Inc | Ozempic (Drug), Rybelsus | Food and Beverage | In-kind items and services | $24.77 | General |
| Category: Diabetes | ||||||
| 11/22/2024 | Abbott Laboratories | AVEIR (Device) | Food and Beverage | In-kind items and services | $11.34 | General |
| Category: Cardiac Rhythm Management | ||||||
| 11/18/2024 | Novartis Pharmaceuticals Corporation | LEQVIO (Drug) | Food and Beverage | In-kind items and services | $23.52 | General |
| Category: Cardiology/Vascular Diseases | ||||||
| 11/01/2024 | Lilly USA, LLC | MOUNJARO (Drug), ZEPBOUND | Food and Beverage | In-kind items and services | $26.51 | General |
| Category: Diabetes | ||||||
| 10/28/2024 | Merck Sharp & Dohme LLC | VERQUVO (Drug), VERQUVO | Food and Beverage | In-kind items and services | $26.25 | General |
| Category: CARDIOVASCULAR | ||||||
| 10/21/2024 | Novartis Pharmaceuticals Corporation | LEQVIO (Drug) | Food and Beverage | In-kind items and services | $25.93 | General |
| Category: Cardiology/Vascular Diseases | ||||||
| 10/21/2024 | Novartis Pharmaceuticals Corporation | LEQVIO (Drug) | Food and Beverage | In-kind items and services | $1.55 | General |
| Category: Cardiology/Vascular Diseases | ||||||
| 10/11/2024 | Merck Sharp & Dohme LLC | VERQUVO (Drug), VERQUVO | Food and Beverage | In-kind items and services | $28.00 | General |
| Category: CARDIOVASCULAR | ||||||
| 10/07/2024 | E.R. Squibb & Sons, L.L.C. | CAMZYOS (Drug) | Food and Beverage | Cash or cash equivalent | $18.79 | General |
| Category: Cardiovascular | ||||||
| 10/04/2024 | Lilly USA, LLC | MOUNJARO (Drug), ZEPBOUND | Food and Beverage | In-kind items and services | $22.60 | General |
| Category: Diabetes | ||||||
| 10/04/2024 | Lilly USA, LLC | MOUNJARO (Drug), ZEPBOUND | Food and Beverage | In-kind items and services | $2.26 | General |
| Category: Diabetes | ||||||
| 09/25/2024 | Abbott Laboratories | AVEIR (Device) | Food and Beverage | In-kind items and services | $19.68 | General |
| Category: Cardiac Rhythm Management | ||||||
| 09/16/2024 | Lilly USA, LLC | MOUNJARO (Drug) | Food and Beverage | In-kind items and services | $23.44 | General |
| Category: Diabetes | ||||||
| 09/15/2024 | Novo Nordisk Inc | Ozempic (Drug), Rybelsus | Food and Beverage | In-kind items and services | $15.52 | General |
| Category: Diabetes | ||||||
| 09/15/2024 | Abbott Laboratories | TENDRIL (Device) | Food and Beverage | In-kind items and services | $6.53 | General |
| Category: Cardiac Rhythm Management | ||||||
| 09/14/2024 | Lilly USA, LLC | MOUNJARO (Drug), ZEPBOUND | Food and Beverage | In-kind items and services | $23.55 | General |
| Category: Diabetes | ||||||
| 09/14/2024 | Lilly USA, LLC | MOUNJARO (Drug), ZEPBOUND | Food and Beverage | In-kind items and services | $1.46 | General |
| Category: Diabetes | ||||||
| 09/09/2024 | Abbott Laboratories | JOT DX (Device) | Food and Beverage | In-kind items and services | $26.78 | General |
| Category: Cardiac Rhythm Management | ||||||
| 09/09/2024 | Merck Sharp & Dohme LLC | VERQUVO (Drug), VERQUVO | Food and Beverage | In-kind items and services | $26.25 | General |
| Category: CARDIOVASCULAR | ||||||
| 09/07/2024 | PFIZER INC. | ELIQUIS (Drug), NURTEC ODT | Food and Beverage | In-kind items and services | $17.93 | General |
| Category: CARDIOVASCULAR;METABOLIC DISEASE | ||||||
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 15 | 1,796 | 3,214 | $817,905 | $339,987 |
| 2022 | 15 | 2,213 | 3,931 | $1.1M | $474,489 |
| 2021 | 14 | 2,109 | 3,526 | $963,675 | $436,989 |
| 2020 | 14 | 2,171 | 3,637 | $984,935 | $433,512 |
Total Patients
8,289
Total Services
14,308
Medicare Billing
$1.7M
Procedure Codes
58
All Medicare Procedures & Services
58 procedure records from CMS Medicare Utilization — Page 1 of 3
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 93229 | Electrocardiogram (ecg) up to 30 days continuous with transmission of patient triggered events with review and report by health care professional | Office | 2023 | 103 | 105 | $136,500 | $83,990 | 61.5% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2023 | 319 | 976 | $122,000 | $71,293 | 58.4% |
| 93306 | Ultrasound of heart with color-depicted blood flow, rate, direction and valve function | Office | 2023 | 233 | 236 | $141,600 | $42,857 | 30.3% |
| 93925 | Ultrasound of leg arteries or artery grafts | Office | 2023 | 179 | 182 | $91,000 | $41,274 | 45.4% |
| 93975 | Complete ultrasound of abdomen and pelvis artery and vein blood flow | Office | 2023 | 131 | 134 | $80,400 | $34,112 | 42.4% |
| 93880 | Ultrasound of both sides of head and neck blood flow | Office | 2023 | 149 | 150 | $75,000 | $27,280 | 36.4% |
| 93000 | Routine electrocardiogram (ecg) using at least 12 leads with interpretation and report | Office | 2023 | 307 | 857 | $55,705 | $10,576 | 19.0% |
| 93015 | Exercise or drug-induced heart stress test with electrocardiogram (ecg) with supervision and review by physician | Office | 2023 | 77 | 78 | $23,400 | $4,961 | 21.2% |
| 99454 | Remote monitoring of physiologic parameters, initial supply of devices with daily recordings or programmed alerts transmission, each 30 days | Office | 2023 | 31 | 96 | $14,400 | $4,268 | 29.6% |
| 99457 | Management using the results of remote vital sign monitoring per calendar month, first 20 minutes | Office | 2023 | 31 | 98 | $14,700 | $4,140 | 28.2% |
| 93970 | Ultrasound study of arm or leg veins with compression and maneuvers | Office | 2023 | 21 | 21 | $10,500 | $3,821 | 36.4% |
| 99458 | Management using the results of remote vital sign monitoring per calendar month, each additional 20 minutes | Office | 2023 | 31 | 95 | $14,250 | $3,232 | 22.7% |
| 99203 | New patient office or other outpatient visit, 30-44 minutes | Office | 2023 | 37 | 37 | $5,550 | $3,012 | 54.3% |
| 93224 | Electrocardiogram (ecg) 2-day continuous with review and report by health care professional | Office | 2023 | 45 | 45 | $22,500 | $2,770 | 12.3% |
| 93228 | Electrocardiogram (ecg) up to 30 days continuous with review and report by health care professional | Office | 2023 | 102 | 104 | $10,400 | $2,402 | 23.1% |
| 93229 | Electrocardiogram (ecg) up to 30 days continuous with transmission of patient triggered events with review and report by health care professional | Office | 2022 | 194 | 195 | $253,500 | $168,997 | 66.7% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2022 | 323 | 935 | $116,875 | $67,641 | 57.9% |
| 93975 | Complete ultrasound of abdomen and pelvis artery and vein blood flow | Office | 2022 | 189 | 189 | $113,400 | $49,248 | 43.4% |
| 93925 | Ultrasound of leg arteries or artery grafts | Office | 2022 | 193 | 194 | $97,000 | $45,498 | 46.9% |
| 93306 | Ultrasound of heart with color-depicted blood flow, rate, direction and valve function | Office | 2022 | 221 | 223 | $133,800 | $41,415 | 31.0% |
| 93880 | Ultrasound of both sides of head and neck blood flow | Office | 2022 | 195 | 197 | $98,500 | $37,147 | 37.7% |
| 93970 | Ultrasound study of arm or leg veins with compression and maneuvers | Office | 2022 | 70 | 71 | $35,500 | $13,161 | 37.1% |
| 93000 | Routine electrocardiogram (ecg) using at least 12 leads with interpretation and report | Office | 2022 | 342 | 992 | $64,480 | $11,926 | 18.5% |
| 99454 | Remote monitoring of physiologic parameters, initial supply of devices with daily recordings or programmed alerts transmission, each 30 days | Office | 2022 | 45 | 184 | $27,600 | $9,765 | 35.4% |
| 99457 | Management using the results of remote vital sign monitoring per calendar month, first 20 minutes | Office | 2022 | 46 | 201 | $30,150 | $9,359 | 31.0% |
About Dr. Ernest Afflu, M.D
Dr. Ernest Afflu, M.D is a Cardiovascular Disease healthcare provider based in Brooklyn, New York. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 06/16/2006. The National Provider Identifier (NPI) number assigned to this provider is 1447294764.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Ernest Afflu, M.D has received a total of $15,165 in payments from pharmaceutical and medical device companies, with $1,819 received in 2024. These payments were reported across 582 transactions from 38 companies. The most common payment nature is "Food and Beverage" ($12,898).
As a Medicare-enrolled provider, Afflu has provided services to 8,289 Medicare beneficiaries, totaling 14,308 services with total Medicare billing of $1.7M. Data is available for 4 years (2020–2023), covering 58 distinct procedure/service records.
Ad
Practice Information
- Specialty Cardiovascular Disease
- Location Brooklyn, NY
- Active Since 06/16/2006
- Last Updated 11/26/2024
- Taxonomy Code 207RC0000X
- Entity Type Individual
- Practice Solo Practitioner
- NPI Number 1447294764
Products in Payments
- EMBLEM (Device) $1,383
- XARELTO (Drug) $1,190
- CardioSight (Device) $1,071
- ENTRESTO (Drug) $1,005
- Repatha (Biological) $758.13
- LifeVest (Device) $672.64
- JARDIANCE (Drug) $636.95
- MOUNJARO (Drug) $598.43
- VERQUVO (Drug) $548.36
- ELIQUIS (Drug) $421.47
- AVEIR (Device) $405.39
- LEQVIO (Drug) $369.84
- AVALUS (Device) $253.66
- Vascepa (Drug) $253.65
- BRILINTA (Drug) $237.85
- PRADAXA (Drug) $230.13
- Ozempic (Drug) $222.39
- PRALUENT (Drug) $216.90
- WATCHMAN (Device) $205.40
- FARXIGA (Drug) $193.67
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Cardiovascular Disease Doctors in Brooklyn
Dr. Felix Yang, M.d, M.D
Cardiovascular Disease — Payments: $599,451
Cardiovascular Disease $599,451
Ozgen Dogan, Md, MD
Cardiovascular Disease — Payments: $367,116
Cardiovascular Disease $367,116
Dr. Adam Budzikowski, M.d., Ph.d, M.D., PH.D
Cardiovascular Disease — Payments: $346,063
Cardiovascular Disease $346,063
Dr. Peter Rouvelas, M.d, M.D
Cardiovascular Disease — Payments: $339,378
Cardiovascular Disease $339,378
Dr. Ronald Wharton, M.d, M.D
Cardiovascular Disease — Payments: $298,083
Cardiovascular Disease $298,083
Dr. Sorin Brener, Md, MD
Cardiovascular Disease — Payments: $225,799
Cardiovascular Disease $225,799